BioCentury | Sep 22, 2014
Finance

Scholar Rock's niche

...with its broad range of disease applications, and a team of founding scientists led by LeukoSite Inc....
BioCentury | Apr 15, 2013
Company News

Ilex, LeukoSite deal

...The companies formed a joint venture to develop Campath-1H , LeukoSite’s monoclonal antibody to treat chronic...
...almost exclusively on lymphocytes. The mechanism destroys malignant cells while sparing the hematopoietic stem cells, LeukoSite...
...depletion was too great for chronic RA therapy. Ilex Oncology Inc. (ILXO), San Antonio, Texas LeukoSite Inc....
BioCentury | Apr 15, 2013
Company News

LeukoSite board of directors update

LeukoSite Inc. , Cambridge, Mass. Business: Infectious diseases/AIDS Appointed: Mark Skaletsky, president and CEO of GelTex Pharmaceuticals Inc. (GELX) WIR Staff...
BioCentury | Apr 15, 2013
Company News

LeukoSite other research news

...treatment, the report concluded. The company has identified small molecule and monoclonal antibody candidate compounds. LeukoSite Inc....
BioCentury | Apr 14, 2008
Strategy

Global millennium

...oncology assets. While Millennium had emerged as an oncology play following the 1999 acquisition of LeukoSite Inc....
BioCentury | Feb 4, 2008
Product Development

Velcade's true believers

...When Millennium Pharmaceuticals Inc. landed Velcade bortezomib through its 1999 acquisition of LeukoSite Inc. for $635 million...
...company to another portfolio company, LeukoSite, for $2.3 million in stock and $430,000 in cash. LeukoSite...
...intrigued by the early data associated with the proteasome inhibitor. Three months later, Millennium bought LeukoSite...
BioCentury | Feb 4, 2008
Product Development

Velcade's history

...North Carolina Jun 1999 LeukoSite acquires ProScript Oct 1999 Millennium (NASDAQ:MLNM) announces deal to acquire LeukoSite...
BioCentury | May 30, 2005
Finance

VPOs into the breach

...acquired by LeukoSite Inc. (Cambridge, Mass.) for $2.3 million in cash and stock. Later that year, LeukoSite...
BioCentury | Jan 5, 2004
Finance

Short-term performance

...$61 Geron (GERN) $80 $139 $59 74% $482 DepoMed (DEPO) $34 $58 $25 73% $208 LeukoSite...
BioCentury | Jan 5, 2004
Finance

Top NASDAQ performers

...$1,197.8 Aviron (A) $90 $1,500 $1,410 1574% $773.6 Abgenix (ABGX) $88 $1,078 $990 1124% $1,075.7 LeukoSite...
Items per page:
1 - 10 of 98
BioCentury | Sep 22, 2014
Finance

Scholar Rock's niche

...with its broad range of disease applications, and a team of founding scientists led by LeukoSite Inc....
BioCentury | Apr 15, 2013
Company News

Ilex, LeukoSite deal

...The companies formed a joint venture to develop Campath-1H , LeukoSite’s monoclonal antibody to treat chronic...
...almost exclusively on lymphocytes. The mechanism destroys malignant cells while sparing the hematopoietic stem cells, LeukoSite...
...depletion was too great for chronic RA therapy. Ilex Oncology Inc. (ILXO), San Antonio, Texas LeukoSite Inc....
BioCentury | Apr 15, 2013
Company News

LeukoSite board of directors update

LeukoSite Inc. , Cambridge, Mass. Business: Infectious diseases/AIDS Appointed: Mark Skaletsky, president and CEO of GelTex Pharmaceuticals Inc. (GELX) WIR Staff...
BioCentury | Apr 15, 2013
Company News

LeukoSite other research news

...treatment, the report concluded. The company has identified small molecule and monoclonal antibody candidate compounds. LeukoSite Inc....
BioCentury | Apr 14, 2008
Strategy

Global millennium

...oncology assets. While Millennium had emerged as an oncology play following the 1999 acquisition of LeukoSite Inc....
BioCentury | Feb 4, 2008
Product Development

Velcade's true believers

...When Millennium Pharmaceuticals Inc. landed Velcade bortezomib through its 1999 acquisition of LeukoSite Inc. for $635 million...
...company to another portfolio company, LeukoSite, for $2.3 million in stock and $430,000 in cash. LeukoSite...
...intrigued by the early data associated with the proteasome inhibitor. Three months later, Millennium bought LeukoSite...
BioCentury | Feb 4, 2008
Product Development

Velcade's history

...North Carolina Jun 1999 LeukoSite acquires ProScript Oct 1999 Millennium (NASDAQ:MLNM) announces deal to acquire LeukoSite...
BioCentury | May 30, 2005
Finance

VPOs into the breach

...acquired by LeukoSite Inc. (Cambridge, Mass.) for $2.3 million in cash and stock. Later that year, LeukoSite...
BioCentury | Jan 5, 2004
Finance

Short-term performance

...$61 Geron (GERN) $80 $139 $59 74% $482 DepoMed (DEPO) $34 $58 $25 73% $208 LeukoSite...
BioCentury | Jan 5, 2004
Finance

Top NASDAQ performers

...$1,197.8 Aviron (A) $90 $1,500 $1,410 1574% $773.6 Abgenix (ABGX) $88 $1,078 $990 1124% $1,075.7 LeukoSite...
Items per page:
1 - 10 of 98